Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting
New evidence from the world’s first genome-wide association study (GWAS) identifies genes and genetic variants associated with bedwetting and may lead to earlier identification of children predisposed to bedwetting and improved earlier treatment options.The results are being presented by the International Children’s Continence Society (ICCS) and the European Society for Paediatric Urology (ESPU) on World Bedwetting Day on 29 May 2018.
“We have known for over a century, there has been strong evidence suggesting a genetic background for bedwetting.2 The risk of bedwetting is 5-7 times higher among children with a parent who suffered from bedwetting as a child, and approximately 11 times higher if both parents were bedwetters”,1 said Dr. Søren Rittig, Professor at the Department of Child and Youth, Nephro-urologic Team, Aarhus University Hospital who together with associate professor Jane Hvarregaard Christensen, Department of Biomedicine, Aarhus University is responsible for this new study.
Bedwetting is a common medical condition that has a serious impact on a child’s self-esteem, emotional well-being and day time functioning, including school and social performance3,4,5; and improvements in their working memory and other daily activities have been seen after treatment.6
The GWAS used the iPSYCH2012 nationwide population-based sample of around 80,000 Danish individuals collected to study among others ADHD and autism. Genome-wide association studies work by scanning markers across the entire genome of large numbers of people in order to find genetic variants associated with a particular disease.
Associate professor Jane Hvarregaard Christensen said, “By comparing the frequency of millions of genetic variants in thousands of DNA samples from bedwetting children we have been able to demonstrate specific genetic variants that each contribute to increase the risk of bedwetting. The genes implicated by this are known to function in deep brain areas responsible for regulation of day-night rhythms, urine production and sleep. This supports that bedwetting is linked to physiological mechanisms rather than being caused by psychological problems.” This is an important first step to provide new insights into the biological processes leading to bedwetting.
There are at least two main reasons why children are bedwetting – a reduced bladder capacity and/or an increased urine production during night-time (polyuria). By analyzing millions of genetic variants in bedwetting children, researchers were able to point to specific genes and thereby suggest specific biological causes of bedwetting.
Dr. Søren Rittig said, “We believe further research using the genes and genetic variants we have detected could help us identify bedwetting children earlier, determine which children would benefit from medication and tailor treatment to alleviate their condition.”
Bedwetting, also known as nocturnal enuresis, is an uncontrollable leakage of urine while asleep.7 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.4 An inability to wake up can be another cause.4 Bedwetting does not seem to have a psychological cause.4 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.8
About World Bedwetting Day
World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated.
World Bedwetting Day 2018 will take place on 29 May and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.
For more information please visit www.worldbedwettingday.com.
About the World Bedwetting Day Steering Committee
The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), and the North American Paediatric Urology Societies. The initiative is supported by Ferring Pharmaceuticals.
1 Jarvelin, M. R., Vikevainen-Tervonen, L., Moilanen, I. &
Huttunen, N. P. Enuresis in seven-year-old children. Acta paediatrica
77, 148-153 (1988).
2 von Gontard, A., Schaumburg, H., Hollmann, E., Eiberg, H. & Rittig, S. The genetics of enuresis: a review. The Journal of urology 166, 2438-2443 (2001).
3 Iannelli V. Bedwetting. Available at https://www.verywell.com/bedwetting-bedwetting-statistics-2633257. Last accessed January 2017.
4 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-98
5 Joinson C et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting Pediatrics. 2007;120(2):e308-16
6 Van Herzeele C, Dhondt K, Roels S P et al. Desmopressin (melt) therapy in children with monosymptomatic nocturnal enuresis and nocturnal polyuria results in improved neuropsychological functioning and sleep. Pediatr Nephrol. 2016; DOI 10.1007/s00467-016-23351-3
7 Austin P et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report from the Standardization Committee of the International Children’s Continence Society, The Journal of Urology. 2014;191:1863-1865
8 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214
Burson-Marsteller, on behalf of World Bedwetting Day Steering Committee
Jack Dixey, +44 (0)207 300 6221
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme